A subset of gastric cancers with EGFR amplification and overexpression respond to cetuximab therapy

A preclinical trial identified 4 of 20 (20%) gastric cancer (GC) patient-derived xenografts responded to cetuximab. Genome-wide profiling and additional investigations revealed that high EGFR mRNA expression and immunohistochemistry score (3+) are associated with tumor growth inhibition. Furthermore...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Lianhai, Yang, Jie, Cai, Jie, Song, Xiaoming, Deng, Jianyun, Huang, Xuesong, Chen, Dawei, Yang, Mengmeng, Wery, Jean-Pierre, Li, Shuangxi, Wu, Aiwen, Li, Ziyu, Li, Zhongwu, Liu, Yiqiang, Chen, Yiyou, Li, Qixiang, Ji, Jiafu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3801116/
https://www.ncbi.nlm.nih.gov/pubmed/24141978
http://dx.doi.org/10.1038/srep02992
_version_ 1782288075349557248
author Zhang, Lianhai
Yang, Jie
Cai, Jie
Song, Xiaoming
Deng, Jianyun
Huang, Xuesong
Chen, Dawei
Yang, Mengmeng
Wery, Jean-Pierre
Li, Shuangxi
Wu, Aiwen
Li, Ziyu
Li, Zhongwu
Liu, Yiqiang
Chen, Yiyou
Li, Qixiang
Ji, Jiafu
author_facet Zhang, Lianhai
Yang, Jie
Cai, Jie
Song, Xiaoming
Deng, Jianyun
Huang, Xuesong
Chen, Dawei
Yang, Mengmeng
Wery, Jean-Pierre
Li, Shuangxi
Wu, Aiwen
Li, Ziyu
Li, Zhongwu
Liu, Yiqiang
Chen, Yiyou
Li, Qixiang
Ji, Jiafu
author_sort Zhang, Lianhai
collection PubMed
description A preclinical trial identified 4 of 20 (20%) gastric cancer (GC) patient-derived xenografts responded to cetuximab. Genome-wide profiling and additional investigations revealed that high EGFR mRNA expression and immunohistochemistry score (3+) are associated with tumor growth inhibition. Furthermore, EGFR amplification were observed in 2/4 (50%) responders with average copy number 5.8 and >15 respectively. Our data suggest that a GC subtype with EGFR amplification and overexpression benefit from cetuximab treatment.
format Online
Article
Text
id pubmed-3801116
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-38011162013-10-21 A subset of gastric cancers with EGFR amplification and overexpression respond to cetuximab therapy Zhang, Lianhai Yang, Jie Cai, Jie Song, Xiaoming Deng, Jianyun Huang, Xuesong Chen, Dawei Yang, Mengmeng Wery, Jean-Pierre Li, Shuangxi Wu, Aiwen Li, Ziyu Li, Zhongwu Liu, Yiqiang Chen, Yiyou Li, Qixiang Ji, Jiafu Sci Rep Article A preclinical trial identified 4 of 20 (20%) gastric cancer (GC) patient-derived xenografts responded to cetuximab. Genome-wide profiling and additional investigations revealed that high EGFR mRNA expression and immunohistochemistry score (3+) are associated with tumor growth inhibition. Furthermore, EGFR amplification were observed in 2/4 (50%) responders with average copy number 5.8 and >15 respectively. Our data suggest that a GC subtype with EGFR amplification and overexpression benefit from cetuximab treatment. Nature Publishing Group 2013-10-21 /pmc/articles/PMC3801116/ /pubmed/24141978 http://dx.doi.org/10.1038/srep02992 Text en Copyright © 2013, Macmillan Publishers Limited. All rights reserved http://creativecommons.org/licenses/by/3.0/ This work is licensed under a Creative Commons Attribution 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by/3.0/
spellingShingle Article
Zhang, Lianhai
Yang, Jie
Cai, Jie
Song, Xiaoming
Deng, Jianyun
Huang, Xuesong
Chen, Dawei
Yang, Mengmeng
Wery, Jean-Pierre
Li, Shuangxi
Wu, Aiwen
Li, Ziyu
Li, Zhongwu
Liu, Yiqiang
Chen, Yiyou
Li, Qixiang
Ji, Jiafu
A subset of gastric cancers with EGFR amplification and overexpression respond to cetuximab therapy
title A subset of gastric cancers with EGFR amplification and overexpression respond to cetuximab therapy
title_full A subset of gastric cancers with EGFR amplification and overexpression respond to cetuximab therapy
title_fullStr A subset of gastric cancers with EGFR amplification and overexpression respond to cetuximab therapy
title_full_unstemmed A subset of gastric cancers with EGFR amplification and overexpression respond to cetuximab therapy
title_short A subset of gastric cancers with EGFR amplification and overexpression respond to cetuximab therapy
title_sort subset of gastric cancers with egfr amplification and overexpression respond to cetuximab therapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3801116/
https://www.ncbi.nlm.nih.gov/pubmed/24141978
http://dx.doi.org/10.1038/srep02992
work_keys_str_mv AT zhanglianhai asubsetofgastriccancerswithegframplificationandoverexpressionrespondtocetuximabtherapy
AT yangjie asubsetofgastriccancerswithegframplificationandoverexpressionrespondtocetuximabtherapy
AT caijie asubsetofgastriccancerswithegframplificationandoverexpressionrespondtocetuximabtherapy
AT songxiaoming asubsetofgastriccancerswithegframplificationandoverexpressionrespondtocetuximabtherapy
AT dengjianyun asubsetofgastriccancerswithegframplificationandoverexpressionrespondtocetuximabtherapy
AT huangxuesong asubsetofgastriccancerswithegframplificationandoverexpressionrespondtocetuximabtherapy
AT chendawei asubsetofgastriccancerswithegframplificationandoverexpressionrespondtocetuximabtherapy
AT yangmengmeng asubsetofgastriccancerswithegframplificationandoverexpressionrespondtocetuximabtherapy
AT weryjeanpierre asubsetofgastriccancerswithegframplificationandoverexpressionrespondtocetuximabtherapy
AT lishuangxi asubsetofgastriccancerswithegframplificationandoverexpressionrespondtocetuximabtherapy
AT wuaiwen asubsetofgastriccancerswithegframplificationandoverexpressionrespondtocetuximabtherapy
AT liziyu asubsetofgastriccancerswithegframplificationandoverexpressionrespondtocetuximabtherapy
AT lizhongwu asubsetofgastriccancerswithegframplificationandoverexpressionrespondtocetuximabtherapy
AT liuyiqiang asubsetofgastriccancerswithegframplificationandoverexpressionrespondtocetuximabtherapy
AT chenyiyou asubsetofgastriccancerswithegframplificationandoverexpressionrespondtocetuximabtherapy
AT liqixiang asubsetofgastriccancerswithegframplificationandoverexpressionrespondtocetuximabtherapy
AT jijiafu asubsetofgastriccancerswithegframplificationandoverexpressionrespondtocetuximabtherapy
AT zhanglianhai subsetofgastriccancerswithegframplificationandoverexpressionrespondtocetuximabtherapy
AT yangjie subsetofgastriccancerswithegframplificationandoverexpressionrespondtocetuximabtherapy
AT caijie subsetofgastriccancerswithegframplificationandoverexpressionrespondtocetuximabtherapy
AT songxiaoming subsetofgastriccancerswithegframplificationandoverexpressionrespondtocetuximabtherapy
AT dengjianyun subsetofgastriccancerswithegframplificationandoverexpressionrespondtocetuximabtherapy
AT huangxuesong subsetofgastriccancerswithegframplificationandoverexpressionrespondtocetuximabtherapy
AT chendawei subsetofgastriccancerswithegframplificationandoverexpressionrespondtocetuximabtherapy
AT yangmengmeng subsetofgastriccancerswithegframplificationandoverexpressionrespondtocetuximabtherapy
AT weryjeanpierre subsetofgastriccancerswithegframplificationandoverexpressionrespondtocetuximabtherapy
AT lishuangxi subsetofgastriccancerswithegframplificationandoverexpressionrespondtocetuximabtherapy
AT wuaiwen subsetofgastriccancerswithegframplificationandoverexpressionrespondtocetuximabtherapy
AT liziyu subsetofgastriccancerswithegframplificationandoverexpressionrespondtocetuximabtherapy
AT lizhongwu subsetofgastriccancerswithegframplificationandoverexpressionrespondtocetuximabtherapy
AT liuyiqiang subsetofgastriccancerswithegframplificationandoverexpressionrespondtocetuximabtherapy
AT chenyiyou subsetofgastriccancerswithegframplificationandoverexpressionrespondtocetuximabtherapy
AT liqixiang subsetofgastriccancerswithegframplificationandoverexpressionrespondtocetuximabtherapy
AT jijiafu subsetofgastriccancerswithegframplificationandoverexpressionrespondtocetuximabtherapy

Ejemplares similares